MAEA Recombinant monoclonal antibody Proteintech 83267-2-RR

$299.00
In stock
SKU
83267-2-RR

 

EMP, EMLP, EC:2.3.2.27, E3 ubiquitin-protein transferase MAEA, Cell proliferation-inducing gene 5 protein

Formulation::PBS, Azide, Glycerol Formulation::PBS, Azide, Glycerol1
Applications:Western Blot (WB) Formulation::PBS, Azide, Glycerol2
 Reactivity:Rabbit / IgG Formulation::PBS, Azide, Glycerol3
Type:CatNo: Ag27150 Product name: Recombinant human MAEA protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 26-239 aa of BC001225 Sequence: YETLNKRFRAAQKNIDRETSHVTMVVAELEKTLSGCPAVDSVVSLLDGVVEKLSVLKRKAVESIQAEDESAKLCKRRIEHLKEHSSDQPAAASVWKRKRMDRMMVEHLLRCGYYNTAVKLARQSGIEDLVNIEMFLTAKEVEESLERRETATCLAWCHDNKSRLRKMKSCLEFSLRIQEFIELIRQNKRLDAVRHARKHFSQAEGSQLDEVRQA Predict reactive species Formulation::PBS, Azide, Glycerol4
RRID:MAEA Formulation::PBS, Azide, Glycerol5
Storage Buffer:Liquid Formulation::PBS, Azide, Glycerol6
Background Information:MAEA(macrophage erythroblast attacher) is a core component of the CTLH E3 ubiquitin-protein ligase complex. MAEA is required for normal cell proliferation and plays a role in erythroblast enucleation during erythrocyte maturation and in the development of mature macrophages. N-terminus MAEA and full-length MAEA are mostly expressed in nuclear and can be detected at low level in the cytoplasm of some cells, while C-terminus MAEA can be detected in the cytoplasm and nucleoli within the nucleus. MAEA mediates the attachment of erythroid cell to mature macrophages which can inhibit erythroid cell apoptosis. The expression of MAEA may be associated with the type 2 diabetes mellitus.(PubMed: 28955747, 24143168, 29911972, 29911972, 30674470, 9763581). Formulation::PBS, Azide, Glycerol7
biogegep8 Formulation::PBS, Azide, Glycerol8
biogegep9 Formulation::PBS, Azide, Glycerol9
Formulation::PBS, Azide, Glycerol0 Applications:Western Blot (WB)0

 

 

Reviews

Write Your Own Review
You're reviewing:MAEA Recombinant monoclonal antibody Proteintech 83267-2-RR
Your Rating
Copyright © 2025 Biogege, Inc. All rights reserved.